PA8454601A1 - Azetidinas - Google Patents

Azetidinas

Info

Publication number
PA8454601A1
PA8454601A1 PA19988454601A PA8454601A PA8454601A1 PA 8454601 A1 PA8454601 A1 PA 8454601A1 PA 19988454601 A PA19988454601 A PA 19988454601A PA 8454601 A PA8454601 A PA 8454601A PA 8454601 A1 PA8454601 A1 PA 8454601A1
Authority
PA
Panama
Prior art keywords
azetidins
tachycinin
xyr
receptors
compounds
Prior art date
Application number
PA19988454601A
Other languages
English (en)
Inventor
Alker David David
Thomas Victor Magee
Graham Nigel Maw
Donald Stuart Middleton
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PA8454601A1 publication Critical patent/PA8454601A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

COMPUESTOS DE FORMULA (1): EN LA QUE X1, A, AR1, X Y R SON COMO SE DEFINE EN LA MEMORIA DESCRIPTIVA, Y SUS SALES FARMACEUTICAMENTE ACEPTABLES, SON NUEVOS, Y SON UTILES COMO INHIBIDORES DE TAQUICININA QUE ACTUAN EN LOS RECEPTORES NK1, NK2 Y NK3, O UNA COMBINACION DE DOS O MAS DE ELLOS.
PA19988454601A 1997-07-04 1998-07-02 Azetidinas PA8454601A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9714129.5A GB9714129D0 (en) 1997-07-04 1997-07-04 Azetidines

Publications (1)

Publication Number Publication Date
PA8454601A1 true PA8454601A1 (es) 2000-05-24

Family

ID=10815370

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19988454601A PA8454601A1 (es) 1997-07-04 1998-07-02 Azetidinas

Country Status (36)

Country Link
US (1) US6262046B1 (es)
EP (1) EP1023285A1 (es)
JP (1) JP2000511207A (es)
KR (1) KR20010015532A (es)
CN (1) CN1261887A (es)
AP (1) AP1110A (es)
AR (1) AR013171A1 (es)
AU (1) AU726708B2 (es)
BG (1) BG103992A (es)
BR (1) BR9810544A (es)
CA (1) CA2294193A1 (es)
CO (1) CO4950604A1 (es)
DZ (1) DZ2550A1 (es)
EA (1) EA002773B1 (es)
GB (1) GB9714129D0 (es)
GT (1) GT199800106A (es)
HN (1) HN1998003689A (es)
HR (1) HRP20000002B1 (es)
HU (1) HUP0002330A3 (es)
ID (1) ID24090A (es)
IL (1) IL133433A0 (es)
IS (1) IS5295A (es)
MA (1) MA26519A1 (es)
NO (1) NO996115L (es)
NZ (1) NZ501715A (es)
OA (1) OA11236A (es)
PA (1) PA8454601A1 (es)
PE (1) PE83999A1 (es)
PL (1) PL338004A1 (es)
SK (1) SK182799A3 (es)
TN (1) TNSN98127A1 (es)
TR (1) TR200000025T2 (es)
TW (1) TW492960B (es)
UY (1) UY25079A1 (es)
WO (1) WO1999001451A1 (es)
ZA (1) ZA985875B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9714129D0 (en) 1997-07-04 1997-09-10 Pfizer Ltd Azetidines
AU1089599A (en) * 1997-10-15 1999-05-03 Coelacanth Chemical Corporation Synthesis of azetidine derivatives
FR2787449B3 (fr) 1998-12-15 2001-01-12 Sanofi Sa Derives de 3-phenyl-2,6-dioxopiperidin-3-yl propionamide et leur procede de preparation
FR2787448B3 (fr) 1998-12-18 2001-01-12 Sanofi Sa Ester d'alkyle inferieur de l'acide 3-(3,4-dihalogenophenyl) -2,6-dioxopiperidine3-propionique et son mode de preparation
FR2805817B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
FR2805810B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
US6566356B2 (en) 2000-03-03 2003-05-20 Aventis Pharma S.A. Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
US7435736B2 (en) * 2002-12-23 2008-10-14 Janssen Pharmaceutica, N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
TW200508221A (en) 2003-06-13 2005-03-01 Astrazeneca Ab New azetidine compounds
FR2876689B1 (fr) * 2004-10-14 2008-02-22 Aventis Pharma Sa Nouveau procede et intermediaires de preparation de derives de n-(1-benzhydryl-azetidin-3-yl)-n-phenyl-methylsulfonamide
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
ES2350647T3 (es) * 2005-03-08 2011-01-25 Janssen Pharmaceutica Nv Derivados de diaza-espiro-[4.4]-nonano como antagonistas de neuroquininas (nk1).
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
TW200815353A (en) 2006-04-13 2008-04-01 Euro Celtique Sa Benzenesulfonamide compounds and their use
US8937181B2 (en) 2006-04-13 2015-01-20 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US8106208B2 (en) 2006-05-18 2012-01-31 Albireo Ab Benzamide compounds that act as NK receptor antagonists
EP2129381A1 (en) 2007-01-24 2009-12-09 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
MX2010001080A (es) 2007-08-07 2010-03-01 Hoffmann La Roche Pirrolidin-aril-eteres como antagonistas de receptor de nk3.
US8765736B2 (en) * 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
SG11201709593VA (en) 2015-06-23 2017-12-28 Eisai R&D Man Co Ltd CRYSTAL OF (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]- 4,7-DIOXO-8-({6-[3-(PIPERAZIN-1-YL)AZETIDIN-1-YL]PYRIDIN- 2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625060A (en) 1991-05-03 1997-04-29 Elf Sanofi Polycyclic amine compounds and their enantiomers, their method of preparation and pharmaceutical compositions on which they are present
FR2676055B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
TW432061B (en) * 1994-08-09 2001-05-01 Pfizer Res & Dev Lactams
FR2729951B1 (fr) * 1995-01-30 1997-04-18 Sanofi Sa Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
GB9600235D0 (en) * 1996-01-05 1996-03-06 Pfizer Ltd Therapeutic agents
GB9601697D0 (en) 1996-01-27 1996-03-27 Pfizer Ltd Therapeutic agents
GB9714129D0 (en) 1997-07-04 1997-09-10 Pfizer Ltd Azetidines

Also Published As

Publication number Publication date
AR013171A1 (es) 2000-12-13
ID24090A (id) 2000-07-06
SK182799A3 (en) 2001-11-06
UY25079A1 (es) 2000-12-29
CA2294193A1 (en) 1999-01-14
TNSN98127A1 (fr) 2005-03-15
AU726708B2 (en) 2000-11-16
AP1110A (en) 2002-10-10
GT199800106A (es) 2000-01-05
NO996115D0 (no) 1999-12-10
TW492960B (en) 2002-07-01
ZA985875B (en) 2000-01-10
KR20010015532A (ko) 2001-02-26
BG103992A (en) 2000-07-31
NZ501715A (en) 2001-06-29
IL133433A0 (en) 2001-04-30
HRP20000002A2 (en) 2000-12-31
OA11236A (en) 2003-05-27
NO996115L (no) 2000-02-22
AP9801291A0 (en) 1998-09-30
PE83999A1 (es) 1999-09-11
HUP0002330A3 (en) 2002-05-28
AU8806298A (en) 1999-01-25
GB9714129D0 (en) 1997-09-10
TR200000025T2 (tr) 2000-06-21
DZ2550A1 (fr) 2003-02-08
BR9810544A (pt) 2000-09-05
JP2000511207A (ja) 2000-08-29
CO4950604A1 (es) 2000-09-01
EP1023285A1 (en) 2000-08-02
IS5295A (is) 1999-12-10
US6262046B1 (en) 2001-07-17
PL338004A1 (en) 2000-09-25
HN1998003689A (es) 1999-01-08
EA002773B1 (ru) 2002-08-29
WO1999001451A1 (en) 1999-01-14
CN1261887A (zh) 2000-08-02
HUP0002330A2 (hu) 2001-06-28
EA199901102A1 (ru) 2000-08-28
MA26519A1 (fr) 2004-12-20
HRP20000002B1 (en) 2002-06-30

Similar Documents

Publication Publication Date Title
PA8454601A1 (es) Azetidinas
FI930772A (fi) Hydroxiureaderivat som saenker glugosnivao i blodet
MX9303100A (es) Nuevos derivados de n-aril- y n-heteroaril-urea como inhibidores de acil-coenzima a: colesterol acil transferasa (acat).
DE69621831D1 (de) Piperazinderivative als tachykinin antagonisten
DK0841928T3 (da) Sustained release-formulering af d-threo-methylphenidat
ES2193508T3 (es) Ftalizinonas.
HN1996000017A (es) Isotiazolonas
NO994877L (no) Kalsilytiske forbindelser
AR003955A1 (es) Derivados de n-(indol-2-carbonil)-glicinamidas, procedimiento para su obtencion y composiciones que los contienen.
PA8467101A1 (es) Compuestos 4-(2-ceto-1-benzilimidazolinil)piperidina como agonistas del receptor orli
ES2175066T3 (es) Antagonistas triciclicos de la vasopresina.
AR010062A1 (es) Nuevos benzamidaldehidos y su utilizacion
DE69811352T2 (de) Integraler schnelldampferzeuger
ES2183331T3 (es) Inhibidores de sulfamida-metaloproteasa.
ES2189235T3 (es) 6-fenilfenantridinas sustituidas.
ES2191180T3 (es) Antagonistas de los receptores de la dopamina benzoxazinona d4.
DK0846242T3 (da) Dampgenerator
PT696194E (pt) Utilizacao de derivados de indole como antagonistas de 5ht1
ES2183923T3 (es) Derivados de cromona.
DE69426452T2 (de) Fibrinogen receptor antagonisten
PA8486701A1 (es) Antagonistas de 5ht1 para terapia antidepresiva
PA8465101A1 (es) Compuestos de triazina
ES2140672T3 (es) Compuestos biciclicos sustituidos, fusionados y puentes utilizados como agentes terapeuticos.
UY26329A1 (es) Antagonistas de los receptores de vitronectina
ECSP982577A (es) Azetidinas